C Diff Drug Development

C Diff Drug Development

974 bookmarks
Custom sorting
Mindy Engevik on Twitter
Mindy Engevik on Twitter
RBX2660 was shown to be safe and effective at reducing recurrence in #Cdiff #infection - great talk by Paul Feuerstadt at #DDW2022 #microbes #treatment pic.twitter.com/1bEk8bxH3S— Mindy Engevik (@MicroMindy) May 24, 2022
·twitter.com·
Mindy Engevik on Twitter
Summit says path forward for failed C. difficile drug is likely through partnerships - FierceBiotech
Summit says path forward for failed C. difficile drug is likely through partnerships - FierceBiotech
Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial.  | Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. It hopes to present more data in May. The blueprint from the company comes after its shares have plummeted 50% in the last six months.
·fiercebiotech.com·
Summit says path forward for failed C. difficile drug is likely through partnerships - FierceBiotech
Hon Wai Koon is showing work that Bacillus velezensis secretes a metabolite that reduces #Cdiff #toxin B #intestinal damage #DDW2022 #microbes
Hon Wai Koon is showing work that Bacillus velezensis secretes a metabolite that reduces #Cdiff #toxin B #intestinal damage #DDW2022 #microbes
Hon Wai Koon is showing work that Bacillus velezensis secretes a metabolite that reduces #Cdiff #toxin B #intestinal damage #DDW2022 #microbes pic.twitter.com/lBG1c3DsQu— Mindy Engevik (@MicroMindy) May 24, 2022
·twitter.com·
Hon Wai Koon is showing work that Bacillus velezensis secretes a metabolite that reduces #Cdiff #toxin B #intestinal damage #DDW2022 #microbes
Antibacterial and Antibiofilm Activities of Some Plant Essential Oils and Synergistic Effects of Cinnamon Essential Oil with Vancomycin against Clostridioides difficile: in vitro study
Antibacterial and Antibiofilm Activities of Some Plant Essential Oils and Synergistic Effects of Cinnamon Essential Oil with Vancomycin against Clostridioides difficile: in vitro study
The detection of resistant strains of Clostridioides difficile against existing antibiotics and the side effects led to the investigation of alternative agents. Inhibition zones of various essential oils to four strains of C.difficile and other Clostridium species ranged from 8.32-44.18 mm. The high …
·pubmed.ncbi.nlm.nih.gov·
Antibacterial and Antibiofilm Activities of Some Plant Essential Oils and Synergistic Effects of Cinnamon Essential Oil with Vancomycin against Clostridioides difficile: in vitro study
Adiso Therapeutics Announces Completion of Enrollment in a Phase 1b Study of ADS024 for the Prevention of C. difficile Recurrence
Adiso Therapeutics Announces Completion of Enrollment in a Phase 1b Study of ADS024 for the Prevention of C. difficile Recurrence
Adiso Therapeutics, Inc. announced the completion of patient enrollment in the Phase 1b clinical study evaluating ADS024, an orally delivered single strain live biotherapeutic product, for the prevention of C. difficile infection recurrence.
·biospace.com·
Adiso Therapeutics Announces Completion of Enrollment in a Phase 1b Study of ADS024 for the Prevention of C. difficile Recurrence
Dr Paul Feuerstadt Explains Findings of PUNCH CD2, CD3 Trials on RBX2660 for Recurrent C difficile
Dr Paul Feuerstadt Explains Findings of PUNCH CD2, CD3 Trials on RBX2660 for Recurrent C difficile
Investigational microbiota-based live therapeutic RBX2660 was found to be safe and effective at reducing Clostridioides difficile (C difficile) recurrence, said Paul Feuerstadt, MD, assistant clinical professor at Yale University School of Medicine, gastroenterologist at PACT Gastroenterology Center, at Digestive Disease Week 2022.
·ajmc.com·
Dr Paul Feuerstadt Explains Findings of PUNCH CD2, CD3 Trials on RBX2660 for Recurrent C difficile
VIDEO: RBX2660 restores microbiome, bile acid composition in C. difficile infection
VIDEO: RBX2660 restores microbiome, bile acid composition in C. difficile infection
SAN DIEGO RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to research at Digestive Disease Week 2022.“This poster is three different takes on how RBX2660 is aimed at restoring the microbiome and the data that we saw in three clinical trials,&rdq
·healio.com·
VIDEO: RBX2660 restores microbiome, bile acid composition in C. difficile infection
Investigational Therapy SER-109 Prevents Recurrent C Difficile Infection
Investigational Therapy SER-109 Prevents Recurrent C Difficile Infection
Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.
·contagionlive.com·
Investigational Therapy SER-109 Prevents Recurrent C Difficile Infection
Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff.
Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff.
“@sanjiv_chopra ➡️Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff. Work in progress on alcoholism, autism, and others. ➡️AI will shape how we practice. EKG can predict cirrhosis ➡️CRISPR will shape the future of the human race @DDWMeeting #DDW2022”
·twitter.com·
Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff.
RESTORE UC study of #FMT superdonors:
RESTORE UC study of #FMT superdonors:
•Randomized, placebo-controlled trial•Standardized anaerobic feces storage •High alpha-diversity donors•Active UC frequently biologic-experienced recipients.•Study stopped early for futility #DDW2022— Kira Newman, MD, PhD (@KiraNewmanMDPhD) May 22, 2022
·twitter.com·
RESTORE UC study of #FMT superdonors:
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.
·ir.serestherapeutics.com·
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes
Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes
Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes pic.twitter.com/mc7hGS0wLB— Mindy Engevik (@MicroMindy) May 21, 2022
·twitter.com·
Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes
Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection
Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection
The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines targeting both toxins through parenteral immunization routes. Recently, we generated a novel chimeric protein …
·pubmed.ncbi.nlm.nih.gov·
Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection